STOCK TITAN

Inovio Pharmaceuticals, Inc. - INO STOCK NEWS

Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a pioneering United States-based biotechnology company dedicated to combating cancers and infectious diseases through DNA medicines. The company's innovative approach harnesses active DNA-based immunotherapies and vaccines to both treat and prevent these conditions.

Inovio's core technology revolves around its DNA plasmids, which are small circular DNA molecules crafted to produce specific proteins to target and fight diseases, delivered via their proprietary CELLECTRA® electroporation devices. This technology enables the body to produce its own disease-fighting proteins and immune responses, without the need for traditional adjuvants or nanoparticles.

The company's flagship candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease caused by HPV-6 and HPV-11. Inovio has shown significant clinical progress with INO-3107, and after receiving Breakthrough Therapy designation and Orphan Drug designation from both the FDA and the European Commission, it is on track to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. With successful clinical trials demonstrating a robust immune response and a reduction in the need for surgical interventions, INO-3107 stands as a potential game-changer for RRP patients.

In addition to INO-3107, Inovio's expansive product pipeline includes several other promising candidates in various stages of development. These include INO-3112 for HPV-16/18 positive head and neck cancer, INO-4201 as an Ebola vaccine booster, and INO-5401 for glioblastoma, showcasing the versatility and broad applicability of the company's DNA medicine platform.

Inovio has established numerous strategic partnerships and collaborations to enhance its research and development efforts. Key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program. These collaborations not only bolster Inovio's scientific capabilities but also facilitate the swift advancement of its clinical programs.

Financially, Inovio has maintained a disciplined approach to managing its resources. The company recently projected its cash runway to extend into the second quarter of 2025, following positive feedback from the FDA on the accelerated approval pathway for INO-3107. This financial stability is crucial as Inovio prepares for potential commercialization of its lead candidates.

Inovio's commitment to innovation and its effective strategic execution position it as a formidable player in the biopharmaceutical industry, dedicated to bringing groundbreaking DNA medicine solutions to market. For more information, visit www.inovio.com.

Rhea-AI Summary
INOVIO to Release Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
conferences earnings
-
Rhea-AI Summary
INOVIO (NASDAQ:INO) announced that Dr. Jacqueline Shea, President and CEO, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will include one-on-one meetings with registered investors and a webcast of the presentation. INOVIO is a biotechnology company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
Rhea-AI Summary
INOVIO (NASDAQ:INO) has announced an equity grant to a newly hired employee under its 2022 Inducement Plan. The grant includes restricted stock units (RSUs) covering 3,750 shares of common stock and an option to purchase 5,833 shares of common stock. The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second, and third anniversaries of the Grant Date. The stock option has an exercise price of $5.39, the closing price of INOVIO's common stock on the Grant Date. The vesting of the RSUs and stock option is subject to the employee's continued employment with INOVIO on the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
Rhea-AI Summary
INOVIO announces a 1-for-12 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of issued and outstanding shares from approximately 280.1 million to approximately 23.3 million, with no change in the par value per share. Fractional shares will not be issued, and stockholders entitled to receive a fractional share will receive a cash payment. The reverse stock split will not reduce the number of authorized shares of the company's common stock, which will remain at 600,000,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.94%
Tags
-
Rhea-AI Summary
INOVIO to participate in a virtual fireside chat to discuss potential treatment of Recurrent Respiratory Papillomatosis (RRP) with key panel participants including Dr. Jacqueline Shea, Dr. Michael Sumner, and Dr. Simon Best. The event will be moderated by Hartaj Singh of Oppenheimer & Co. Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences
-
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
none
Rhea-AI Summary
INOVIO (NASDAQ: INO) plans to submit a Biological License Application (BLA) for INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), in the second half of 2024. The company aims to request a Priority Review from the FDA, with plans to launch INO-3107 in 2025. If approved, it would be the first DNA medicine for RRP patients in the US and INOVIO's first approved product. The company has already received Orphan Drug and Breakthrough Therapy designations from the FDA, as well as Orphan Drug designation from the European Commission. INOVIO's delivery device, CELLECTRA®, has also received CE marking. The request for Rolling Submission and Priority Review aims to expedite the review process, potentially shortening the FDA's review timeline to approximately six months from the time of submission acceptance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
Rhea-AI Summary
INO Achieves Breakthrough Therapy Designation for INO-3107, Accelerates Commercialization Strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
-
Rhea-AI Summary
INOVIO has announced an equity grant to a newly hired employee under its 2022 Inducement Plan. The grant consists of an option to purchase 15,625 shares of common stock at an exercise price of $0.36, the closing price on the grant date. The option will vest over a period of four years, with one-fourth of the shares vesting on the grant date and an additional one-fourth vesting on each anniversary of the grant date. The employee's continued employment with INOVIO is required for the option to vest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Rhea-AI Summary
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences earnings

FAQ

What is the current stock price of Inovio Pharmaceuticals (INO)?

The current stock price of Inovio Pharmaceuticals (INO) is $1.84 as of December 20, 2024.

What is the market cap of Inovio Pharmaceuticals (INO)?

The market cap of Inovio Pharmaceuticals (INO) is approximately 66.6M.

What is Inovio Pharmaceuticals' primary focus?

Inovio Pharmaceuticals focuses on developing DNA medicines to treat and prevent cancers and infectious diseases.

What is INO-3107?

INO-3107 is Inovio's lead candidate aimed at treating Recurrent Respiratory Papillomatosis (RRP), showing significant clinical efficacy and safety.

What is the CELLECTRA® device?

CELLECTRA® is Inovio's proprietary delivery device that helps DNA medicines enter the body's cells effectively without traditional adjuvants or nanoparticles.

Who are some of Inovio’s key partners?

Inovio's key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program.

What financial outlook has Inovio projected?

Inovio estimates its cash runway to extend into the second quarter of 2025, supported by positive FDA feedback on INO-3107's accelerated approval pathway.

What is INO-3112?

INO-3112 is a DNA medicine candidate for HPV-16/18 positive head and neck cancer, currently being evaluated in combination with PD-1 inhibitors.

How does Inovio's DNA medicines platform work?

Inovio's platform uses precisely designed DNA plasmids delivered by CELLECTRA® devices to produce specific proteins that teach the body to fight diseases.

What are some of Inovio’s recent achievements?

Recent achievements include INO-3107 receiving Breakthrough Therapy designation, clinical collaborations, and advancing their product pipeline.

Where can I find more financial information about Inovio?

Additional financial information can be accessed on Inovio's website at http://ir.inovio.com/financials/default.aspx.

What is Inovio's approach to commercialization?

Inovio has an accelerated commercialization strategy for its leading candidates, with plans to submit regulatory applications and prepare for potential market launches.

Inovio Pharmaceuticals, Inc.

Nasdaq:INO

INO Rankings

INO Stock Data

66.60M
25.88M
0.85%
33.51%
13.5%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN DIEGO